{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:02:21Z","timestamp":1770040941716,"version":"3.49.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/cad.0b013e32835aa5fd","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T09:40:35Z","timestamp":1350466835000},"page":"90-97","source":"Crossref","is-referenced-by-count":32,"title":["Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs"],"prefix":"10.1097","volume":"24","author":[{"given":"Giuseppe","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fable","family":"Zustovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Fiduccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Della Puppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Bertorelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina P.","family":"Gardiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Banzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ciccarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210227","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2009-0235","article-title":"Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.","volume":"15","author":"Girardi","year":"2010","journal-title":"Oncologist"},{"key":"R2-10-20210227","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"R3-10-20210227","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R4-10-20210227","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.","volume":"16","author":"Mir","year":"2011","journal-title":"Oncologist"},{"key":"R5-10-20210227","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-10-20210227","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-10-20210227","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-10-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.","volume":"29","author":"Lai","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-10-20210227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","article-title":"Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.","volume":"101","author":"Reardon","year":"2011","journal-title":"J Neurooncol"},{"key":"R10-10-20210227","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","article-title":"Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.","volume":"20","author":"Bono","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"R11-10-20210227","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/jco.2011.29.15_suppl.2021","article-title":"The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM) abstract.","volume":"29","author":"Nangia","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-10-20210227","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-009-0003-5","article-title":"Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.","volume":"97","author":"Wick","year":"2010","journal-title":"J Neurooncol"},{"key":"R13-10-20210227","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma.","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"R14-10-20210227","first-page":"143","article-title":"Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.","volume":"13","author":"Prados","year":"2011","journal-title":"Neurooncol"},{"key":"R15-10-20210227","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.","volume":"28","author":"Batchelor","year":"2010","journal-title":"J Clin Oncol"},{"key":"R16-10-20210227","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","article-title":"Phase IIIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.","volume":"28","author":"Stupp","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e32835aa5fd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:17:51Z","timestamp":1620947871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201301000-00010"}},"subtitle":["a single-center experience and a critical review of the literature"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32835aa5fd","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}